Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 4/20 | 0.71 |
| ▸ | PGK2 | P07205 | 4/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.65 |
| ▸ | PTPN5 | P54829 | 5/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428108 | 0.79 | PTPN1 (1.00) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL6766314 | 0.75 | PTPN1 (0.50) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL14076365 | 0.74 | PGK1 (0.78) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL6766182 | 0.74 | PGK1 (0.37) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL6155317 | 0.74 | PGK1 (0.78) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL2637465 | 0.74 | PGK1 (0.78) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL6838700 | 0.74 | PGK1 (0.78) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL5499239 | 0.74 | PGK1 (0.78) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL20190977 | 0.71 | PGK1 (0.72) | PGK1PGK2PTPN1PTPN5PTPN2 | |
| SCHEMBL4900949 | 0.70 | PTPN1 (0.44) | PGK1PGK2PTPN1PTPN2PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | claimed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | claimed |
| US-7037912-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2006-05-02 | — | — | US | claimed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20050261318-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-11-24 | — | — | US | claimed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | claimed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | claimed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | claimed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1786421-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| US-7037912-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| WO-2006017124-A2 | OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-11-25 | — | — | US | disclosed |
| US-6750241-B2 | Protein kinase inhibitors | THERAVANCE, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020177600-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-11-28 | — | — | US | disclosed |
| US-20020002169-A1 | Protein kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC | 2002-01-03 | — | — | US | disclosed |
| WO-2001042243-A2 | PROTEIN KINASE INHIBITORS | ADVANCED MEDICINE, INC. (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177600-A1 | Protein kinase inhibitors | MAP3K20, MAP3K9, MAP3K6 | PGK1 300/4885PGK2 264/4885PTPN1 553/4885 |
| US-20020002169-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | PGK1 297/4885PGK2 244/4885PTPN1 633/4885 |
| US-20060135483-A1 | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases | PTPRO, PTPRG, PTPN1 | PGK1 515/4885PGK2 497/4885PTPN1 3/4885 |
| US-20050261318-A1 | Protein kinase inhibitors | MAP3K20, MAP3K6, MAP4K2 | PGK1 297/4885PGK2 244/4885PTPN1 633/4885 |
| US-20040235870-A1 | Enzyme inhibitor contains two or more ligand moieties comprising pyrimidinyl groups covalently linked together by linking groups; keratitis, diabetic retinopathy, angiogenesis, vision defects, ischemia, atherosclerosis,psoriasis, cancer, cirrhosis, diabetes, arthritis, autoimmune disease | UACA, PRKDC, CDK2 | PGK1 368/4885PGK2 299/4885PTPN1 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.